Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9HAT2

UPID:
SIAE_HUMAN

ALTERNATIVE NAMES:
H-Lse; Sialic acid-specific 9-O-acetylesterase

ALTERNATIVE UPACC:
Q9HAT2; B3KPB0; Q8IUT9; Q9HAU7; Q9NT71

BACKGROUND:
The enzyme Sialate O-acetylesterase, with alternative names H-Lse and Sialic acid-specific 9-O-acetylesterase, is pivotal in the regulation of sialic acid dynamics on cell surfaces. By catalyzing the removal of O-acetyl groups from N-acetylneuraminic acid, it influences cell-cell interaction, signaling, and microbial recognition.

THERAPEUTIC SIGNIFICANCE:
Sialate O-acetylesterase's role in autoimmune disease type 6, affecting susceptibility to a spectrum of autoimmune disorders, underscores its therapeutic potential. Targeting this enzyme could lead to innovative treatments for diseases like systemic lupus erythematosus and Crohn disease, highlighting the importance of further research into its functions and mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.